AALL1931: JZP458-201: An Open Label Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia ALL/Lymphoblastic Lymphoma LBL Following Hypersensitivity to E. coli-derived Asparaginases

Brief description of study

The purpose of the study is to learn more about the pharmacology or how your body handles Recombinant Crisantaspase produced in Pseudomonas fluorescens or RC-P (JZP-458) as well as its side effects. The study tests a different form of asparaginase (RC-P) and we want to know how this drug is working in your body. The study drug asparaginase (RC-P) is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s20-00376
ClinicalTrials.gov Identifier: NCT04145531
Principal Investigator: Elizabeth A Raetz.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.